Women with breast cancer are twice as likely to return to work after treatment if their employer makes accommodations for them, but workplace accommodation and job retention are significantly lower for low-income and minority women.
Job loss is an often overlooked side effect of undergoing breast cancer treatment, as an estimated 20% to 30% of survivors do not go back to work 3 to 18 months after diagnosis. Previous research has found that the odds of having a job to return to after treatment are significantly better for women whose employers made accommodations for them during treatment, like providing schedule flexibility around chemotherapy appointments.
However, most studies on job retention after breast cancer have examined white, middle-class women with health insurance. Research on breast cancer’s effects on low-income and minority women has been limited, but a study of Medicaid-insured breast cancer survivors in California found just 60% were working 3 years after their diagnosis.
A study recently published in Health Affairs set out to analyze the relationship between income and job retention for racial/ethnic minority and low-income women who were being treated for breast cancer in New York City. After oversampling to include more low-income and minority women, the researchers asked 319 participants about their employment status, household income, insurance type, job tenure, and other sociodemographic characteristics. The dependent variable, measured in a follow-up survey 4 months after the end of treatment, was job retention defined as having a job or being on sick or disability leave from work at that time.
The total proportion of women working at follow-up was relatively high at 81%, but income-based disparities in job retention were profound. Just 57% of the low-income women (defined as household income less than 200% of the federal poverty level) had kept their jobs, compared to 90% of middle-income and 95% of high-income women. Race was also a factor in job retention; 98% of white women kept their jobs, while only 68% of Chinese women and 73% of Korean women returned to work.
After performing multivariable analysis, the researchers found that the women had significantly lower probabilities of job retention if they were Chinese or low-income, but were 6 times more likely to return to work if they had employer-sponsored health insurance than if they had public insurance or were uninsured.
Women who had accommodating employers were more than twice as likely to return to work after treatment, but the presence of this factor also varied based on sociodemographic characteristics. Being in the low-income group and being Chinese were both associated with lower chances of having an accommodating employer. When controlling for race and ethnicity, women who spoke primarily English or had worked at their jobs for a longer time were more likely to state that their place of employment had been accommodating of their treatment.
The Americans with Disabilities Act was designed to provide job protection for employees with disabilities and illnesses like cancer, but the study authors reported that over half of the low-income women surveyed were not covered under this law because their workplace employed less than 15 people. They recommended expanding the act to include all workers by providing tax credits to small businesses that accommodate their disabled workers.
“Breast cancer survivors who do not continue to work during treatment or return to work soon after its completion are likely to suffer long-term job loss,” the authors noted. “Therefore, job protections are critical to an already vulnerable population of low-income women.”
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More